HIGHLIGHTS
- who: Background et al. from the National Institute of Clinical Excellance (NICE) United Aberdeen, ZN, UK have published the research: New features in MEK retinopathy, in the Journal: (JOURNAL)
SUMMARY
Of molecularly targeted therapy have revolutionized the cancer treatment and increased the Tyagi and Santiago BMC Ophthalmology 2018, 18(Suppl 1):221 survival rate. Most of these agents are associated with ocular toxicities. These agents are relatively new and recently approved by NICE for clinical use in cancer treatment. Awareness of ocular symptoms, side-effect profile of drugs, monitoring regime and liaison between . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.